Novel targeted therapies tailored to the molecular profile of tumors have revolutionized the treatment landscape for advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), showcasing notable progression-free survival rates. These emerging therapies, leveraging kinase inhibitors, exhibit a remarkable capacity to restore iodide uptake in RAI-R thyroid cancer cells. However, successful implementation relies on crucial factors like adopting a multidisciplinary team approach and timely initiation of targeted therapies.
Key words: Multidisciplinary team, Progression-free survival, Targeted therapies, Thyroid cancer.
|
Download PDF 
Post
